Back to Search
MARSHA TALLMAN, M.D.
M.D.
Emergency Medicine Physician
NPI: 1467601864Individual
Specialties, Licenses & Credentials
Emergency Medicine PhysicianPrimary
Emergency Medicine
Code: 207P00000X
MT192811(PA)
Research & Publications (20)
The expanding role of arsenic in acute promyelocytic leukemia.
PMID 18760708·Semin Hematol·2008
6-review
What is the role of arsenic in newly diagnosed APL?
PMID 19041605·Best Pract Res Clin Haematol·2008
6-review
Altered pharmacokinetics of omeprazole in cystic fibrosis knockout mice relative to wild-type mice.
PMID 15319328·Drug Metab Dispos·2004
4-observational
Intravascular clotting activation and bleeding in patients with hematologic malignancies.
PMID 16029967·Rev Clin Exp Hematol·2004
6-review
Effects of all-trans retinoic acid or chemotherapy on the molecular regulation of systemic blood coagulation and fibrinolysis in patients with acute promyelocytic leukemia.
PMID 15304040·J Thromb Haemost·2004
8-other
Acute promyelocytic leukemia as a paradigm for targeted therapy.
PMID 15190513·Semin Hematol·2004
6-review
All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol.
PMID 12393590·Blood·2002
3-trial
Bing-Neel syndrome: an illustrative case and a comprehensive review of the published literature.
PMID 19618118·J Neurooncol·2010
5-case
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol.
PMID 19635999·J Clin Oncol·2009
8-other
Host genetic variants in the interleukin-6 promoter predict poor outcome in patients with estrogen receptor-positive, node-positive breast cancer.
PMID 19435922·Cancer Res·2009
8-other
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
PMID 19369231·Blood·2009
3-trial
Phase I/II trial of AEG35156 X-linked inhibitor of apoptosis protein antisense oligonucleotide combined with idarubicin and cytarabine in patients with relapsed or primary refractory acute myeloid leukemia.
PMID 19652057·J Clin Oncol·2009
3-trial
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996).
PMID 19564636·Blood·2009
3-trial
Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?
PMID 19636013·J Clin Oncol·2009
8-other
Quality of reporting of serious adverse drug events to an institutional review board: a case study with the novel cancer agent, imatinib mesylate.
PMID 19458059·Clin Cancer Res·2009
8-other
Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies.
PMID 19420352·Blood·2009
8-other
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation.
PMID 19652201·Blood·2009
3-trial
Mutational analysis of candidate tumor-associated genes in acute megakaryoblastic leukemia.
PMID 19657363·Leukemia·2009
8-other
Optimizing the CD34 + cell dose for reduced-intensity allogeneic hematopoietic stem cell transplantation.
PMID 19603344·Leuk Lymphoma·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 320 E NORTH AVE
PITTSBURGH, PA 15212 - Phone
- (212) 359-4905
Quick Facts
- NPI
- 1467601864
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile